GSK plc (GSK) announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV) vaccine, Arexvy, for protection against lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older, including those who are at increased risk of the disease over three RSV seasons. New data from the above mentioned study showed that treatment with a single dose of Arexvy cumulative effi ...

Share price of the British pharmaceutical company GSK (NYSE: GSK ) has gone nowhere since I last wrote about at the end of July. Until yesterday, that is, when it spiked by ~6% following news that the company had Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants ...

KEY TAKEAWAYS GSK shares in London jumped 5% Thursday after the British pharmaceutical giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer. The London-listed firm said it had struck agreements to resolve 93%, or about 80,000, of the pending Zantac lawsuits in the U.S. and will make a total payment of up to $2.2 billion to settle them. GSK said the plaintiffs are unanimously recommending their clients accept the settlement. ...

In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication. Thanks largely to news of a crucial legal settlement, GSK (GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively bidding the company's shares up by 5.8% on the day, a performance that easily eclipsed the 0.7% rise of the benchmark S&P 500 index. $2.2 billion-plus in settlements That news concerns a discontinued version of GSK ...

The British drugmaker GSK has struck an agreement to make a payment of up to $2.2bn (£1.7bn) to resolve litigation brought in the US over its heartburn treatment Zantac. The company said it had struck agreements with 10 plaintiff law firms who represent about 93%, roughly 80,000, of the US state court product liability cases pending against it. The company said in a stock market statement on Wednesday that it would make the aggregate payment to resolve all such cases handled by those plaintiff firms that me ...

GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlements with 10 plaintiff firms, which represent a significant 93% of the cases filed against the pharmaceutical company regarding Zantac. The total settlement amount is up to $2.2 billion. ...

GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjusted for seasonal factors, stands at 62.9% for the elderly. This data is crucial for advisory panels, doctors, and patients when deciding which RSV vaccine to choose, as GSK faces strong competition from Pfizer (PFE) and Moderna (MRNA). The vaccine is approved for all adults aged 60 and above in the US and EU, as ...

Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States. Major vaccine manufacturers, including GlaxoSmithKline (GSK, Financial), Moderna, and Pfizer, face decreasing demand as independent pharmacists report a two-thirds decline in RSV vaccine uptake compared to the previous year. RSV poses a severe health risk to infants, older adults, and individuals with compromised immune systems, leading to numerous hospitalizations and deaths annually ...

GSK plc (GSK) announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older). The study achieved its primary endpoint of non-inferior immune response — study participants who received the co-administered shot generated immune responses that were similar to those generated in participants who received each vaccine separately. Study participants who received t ...

Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer September 16, 2024 8:00 AM EDT | Source: Kalm Therapeutics Inc. Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer. Dr. Maeda-Chubachi, a board-certified dermatologist will oversee the design and submission of our Phase 1b/2a clinical trial protocol to the FDA. "Altho ...